An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Clinical trial NCT04076059 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04076059
- Sponsor
- Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-11
- Primary completion
- 2022-11-18
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.